25 XP   0   0   10

BiVictriX Therapeutics PLC
Buy, Hold or Sell?

Let's analyse Bivictrix together

PenkeI guess you are interested in BiVictriX Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BiVictriX Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about BiVictriX Therapeutics PLC

I send you an email if I find something interesting about BiVictriX Therapeutics PLC.

Quick analysis of Bivictrix (30 sec.)










What can you expect buying and holding a share of Bivictrix? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p4.79
Expected worth in 1 year
p-6.69
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
p-11.49
Return On Investment
-99.9%

For what price can you sell your share?

Current Price per Share
p11.50
Expected price per share
p11.00 - p11.50
How sure are you?
50%

1. Valuation of Bivictrix (5 min.)




Live pricePrice per Share (EOD)

p11.50

Intrinsic Value Per Share

p-50.67 - p-60.69

Total Value Per Share

p-45.88 - p-55.89

2. Growth of Bivictrix (5 min.)




Is Bivictrix growing?

Current yearPrevious yearGrowGrow %
How rich?$4.9m$7.8m-$2.9m-59.9%

How much money is Bivictrix making?

Current yearPrevious yearGrowGrow %
Making money-$3.1m-$2.9m-$196.4k-6.3%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Bivictrix (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Bivictrix? (5 min.)

Welcome investor! Bivictrix's management wants to use your money to grow the business. In return you get a share of Bivictrix.

What can you expect buying and holding a share of Bivictrix?

First you should know what it really means to hold a share of Bivictrix. And how you can make/lose money.

Speculation

The Price per Share of Bivictrix is p11.50. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Bivictrix.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Bivictrix, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p4.79. Based on the TTM, the Book Value Change Per Share is p-2.87 per quarter. Based on the YOY, the Book Value Change Per Share is p-1.31 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Bivictrix.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.04-0.3%-0.04-0.3%-0.04-0.3%-0.02-0.2%-0.02-0.2%
Usd Book Value Change Per Share-0.04-0.3%-0.04-0.3%-0.02-0.1%0.010.1%0.010.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-0.3%-0.04-0.3%-0.02-0.1%0.010.1%0.010.1%
Usd Price Per Share0.21-0.21-0.38-0.12-0.12-
Price to Earnings Ratio-5.62--5.62--10.74--3.27--3.27-
Price-to-Total Gains Ratio-5.92--5.92--23.29--14.60--14.60-
Price to Book Ratio3.55-3.55-3.97-1.50-1.50-
Price-to-Total Gains Ratio-5.92--5.92--23.29--14.60--14.60-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.143014
Number of shares6992
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.01
Usd Total Gains Per Share-0.040.01
Gains per Quarter (6992 shares)-249.7183.38
Gains per Year (6992 shares)-998.85333.54
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-999-10090334324
20-1998-20080667658
30-2997-300701001992
40-3995-4006013341326
50-4994-5005016681660
60-5993-6004020011994
70-6992-7003023352328
80-7991-8002026682662
90-8990-9001030022996
100-9988-10000033353330

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.05.00.00.0%0.05.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.03.00.040.0%2.03.00.040.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.05.00.0%0.00.05.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.03.00.040.0%2.03.00.040.0%

Fundamentals of Bivictrix

About BiVictriX Therapeutics PLC

BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-20 03:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of BiVictriX Therapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bivictrix earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Bivictrix to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that 0.00 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BiVictriX Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y--438.4%+438.4%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient Bivictrix is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bivictrix to the Biotechnology industry mean.
  • -55.0% Return on Assets means that Bivictrix generated -0.55 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BiVictriX Therapeutics PLC:

  • The MRQ is -55.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -55.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-55.0%TTM-55.0%0.0%
TTM-55.0%YOY-34.0%-21.1%
TTM-55.0%5Y-71.4%+16.3%
5Y-71.4%10Y-71.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-55.0%-13.5%-41.5%
TTM-55.0%-12.9%-42.1%
YOY-34.0%-11.8%-22.2%
5Y-71.4%-14.1%-57.3%
10Y-71.4%-16.0%-55.4%
1.1.3. Return on Equity

Shows how efficient Bivictrix is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bivictrix to the Biotechnology industry mean.
  • -63.1% Return on Equity means Bivictrix generated -0.63 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BiVictriX Therapeutics PLC:

  • The MRQ is -63.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -63.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-63.1%TTM-63.1%0.0%
TTM-63.1%YOY-37.0%-26.1%
TTM-63.1%5Y-91.0%+27.9%
5Y-91.0%10Y-91.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-63.1%-16.9%-46.2%
TTM-63.1%-16.1%-47.0%
YOY-37.0%-15.1%-21.9%
5Y-91.0%-19.9%-71.1%
10Y-91.0%-20.9%-70.1%

1.2. Operating Efficiency of BiVictriX Therapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bivictrix is operating .

  • Measures how much profit Bivictrix makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bivictrix to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BiVictriX Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y--477.4%+477.4%
10Y--625.6%+625.6%
1.2.2. Operating Ratio

Measures how efficient Bivictrix is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are 0.00 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of BiVictriX Therapeutics PLC:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y-5.679-5.679
10Y-7.894-7.894

1.3. Liquidity of BiVictriX Therapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bivictrix is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.14 means the company has 10.14 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of BiVictriX Therapeutics PLC:

  • The MRQ is 10.141. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.141. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.141TTM10.1410.000
TTM10.141YOY17.261-7.121
TTM10.1415Y12.573-2.433
5Y12.57310Y12.5730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.1413.914+6.227
TTM10.1414.220+5.921
YOY17.2615.388+11.873
5Y12.5736.045+6.528
10Y12.5736.406+6.167
1.3.2. Quick Ratio

Measures if Bivictrix is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bivictrix to the Biotechnology industry mean.
  • A Quick Ratio of 9.85 means the company can pay off 9.85 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BiVictriX Therapeutics PLC:

  • The MRQ is 9.852. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.852. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.852TTM9.8520.000
TTM9.852YOY16.683-6.832
TTM9.8525Y12.373-2.521
5Y12.37310Y12.3730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.8523.572+6.280
TTM9.8523.998+5.854
YOY16.6835.390+11.293
5Y12.3735.969+6.404
10Y12.3736.287+6.086

1.4. Solvency of BiVictriX Therapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bivictrix assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bivictrix to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Bivictrix assets are financed with 12.8% credit (debt) and the remaining percentage (100% - 12.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BiVictriX Therapeutics PLC:

  • The MRQ is 0.128. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.128. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.128TTM0.1280.000
TTM0.128YOY0.081+0.047
TTM0.1285Y0.137-0.009
5Y0.13710Y0.1370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1280.336-0.208
TTM0.1280.334-0.206
YOY0.0810.269-0.188
5Y0.1370.366-0.229
10Y0.1370.390-0.253
1.4.2. Debt to Equity Ratio

Measures if Bivictrix is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bivictrix to the Biotechnology industry mean.
  • A Debt to Equity ratio of 14.6% means that company has 0.15 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BiVictriX Therapeutics PLC:

  • The MRQ is 0.146. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.146. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.146TTM0.1460.000
TTM0.146YOY0.088+0.059
TTM0.1465Y0.176-0.029
5Y0.17610Y0.1760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1460.382-0.236
TTM0.1460.396-0.250
YOY0.0880.335-0.247
5Y0.1760.434-0.258
10Y0.1760.465-0.289

2. Market Valuation of BiVictriX Therapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Bivictrix generates.

  • Above 15 is considered overpriced but always compare Bivictrix to the Biotechnology industry mean.
  • A PE ratio of -5.62 means the investor is paying -5.62 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BiVictriX Therapeutics PLC:

  • The EOD is -3.801. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.619. Based on the earnings, the company is expensive. -2
  • The TTM is -5.619. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.801MRQ-5.619+1.818
MRQ-5.619TTM-5.6190.000
TTM-5.619YOY-10.739+5.120
TTM-5.6195Y-3.271-2.347
5Y-3.27110Y-3.2710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.801-2.259-1.542
MRQ-5.619-2.569-3.050
TTM-5.619-2.664-2.955
YOY-10.739-4.120-6.619
5Y-3.271-6.258+2.987
10Y-3.271-6.171+2.900
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BiVictriX Therapeutics PLC:

  • The EOD is -3.406. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.036. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.036. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.406MRQ-5.036+1.629
MRQ-5.036TTM-5.0360.000
TTM-5.036YOY-13.724+8.689
TTM-5.0365Y-3.752-1.284
5Y-3.75210Y-3.7520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.406-2.924-0.482
MRQ-5.036-3.246-1.790
TTM-5.036-3.488-1.548
YOY-13.724-5.620-8.104
5Y-3.752-8.315+4.563
10Y-3.752-8.826+5.074
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bivictrix is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.55 means the investor is paying 3.55 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of BiVictriX Therapeutics PLC:

  • The EOD is 2.398. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.545. Based on the equity, the company is fair priced.
  • The TTM is 3.545. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.398MRQ3.545-1.147
MRQ3.545TTM3.5450.000
TTM3.545YOY3.972-0.426
TTM3.5455Y1.503+2.042
5Y1.50310Y1.5030.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3981.851+0.547
MRQ3.5452.090+1.455
TTM3.5452.095+1.450
YOY3.9722.844+1.128
5Y1.5033.466-1.963
10Y1.5033.815-2.312
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of BiVictriX Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.872-2.8720%-1.307-54%0.959-399%0.959-399%
Book Value Per Share--4.7954.7950%7.667-37%4.406+9%4.406+9%
Current Ratio--10.14110.1410%17.261-41%12.573-19%12.573-19%
Debt To Asset Ratio--0.1280.1280%0.081+59%0.137-7%0.137-7%
Debt To Equity Ratio--0.1460.1460%0.088+67%0.176-17%0.176-17%
Dividend Per Share----0%-0%-0%-0%
Eps---3.026-3.0260%-2.835-6%-1.466-52%-1.466-52%
Free Cash Flow Per Share---3.376-3.3760%-2.219-34%-1.378-59%-1.378-59%
Free Cash Flow To Equity Per Share---3.376-3.3760%6.302-154%0.760-544%0.760-544%
Gross Profit Margin--1.0001.0000%1.0000%1.0020%1.0020%
Intrinsic Value_10Y_max---60.688--------
Intrinsic Value_10Y_min---50.670--------
Intrinsic Value_1Y_max---2.853--------
Intrinsic Value_1Y_min---2.772--------
Intrinsic Value_3Y_max---11.032--------
Intrinsic Value_3Y_min---10.375--------
Intrinsic Value_5Y_max---22.178--------
Intrinsic Value_5Y_min---20.162--------
Market Cap949050104.000-48%1402943632.0001402943632.0000%2512919623.200-44%783172651.040+79%783172651.040+79%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio2.398-48%3.5453.5450%3.972-11%1.503+136%1.503+136%
Pe Ratio-3.801+32%-5.619-5.6190%-10.739+91%-3.271-42%-3.271-42%
Price Per Share11.500-48%17.00017.0000%30.450-44%9.490+79%9.490+79%
Price To Free Cash Flow Ratio-3.406+32%-5.036-5.0360%-13.724+173%-3.752-25%-3.752-25%
Price To Total Gains Ratio-4.004+32%-5.920-5.9200%-23.289+293%-14.604+147%-14.604+147%
Quick Ratio--9.8529.8520%16.683-41%12.373-20%12.373-20%
Return On Assets---0.550-0.5500%-0.340-38%-0.714+30%-0.714+30%
Return On Equity---0.631-0.6310%-0.370-41%-0.910+44%-0.910+44%
Total Gains Per Share---2.872-2.8720%-1.307-54%0.959-399%0.959-399%
Usd Book Value--4920925.2004920925.2000%7868257.200-37%4521729.600+9%4521729.600+9%
Usd Book Value Change Per Share---0.036-0.0360%-0.016-54%0.012-399%0.012-399%
Usd Book Value Per Share--0.0600.0600%0.095-37%0.055+9%0.055+9%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.038-0.0380%-0.035-6%-0.018-52%-0.018-52%
Usd Free Cash Flow---3464669.600-3464669.6000%-2277031.600-34%-1414470.640-59%-1414470.640-59%
Usd Free Cash Flow Per Share---0.042-0.0420%-0.028-34%-0.017-59%-0.017-59%
Usd Free Cash Flow To Equity Per Share---0.042-0.0420%0.078-154%0.009-544%0.009-544%
Usd Market Cap11802387.093-48%17447007.00817447007.0080%31250668.434-44%9739535.088+79%9739535.088+79%
Usd Price Per Share0.143-48%0.2110.2110%0.379-44%0.118+79%0.118+79%
Usd Profit---3105269.200-3105269.2000%-2908780.400-6%-1504258.560-52%-1504258.560-52%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.036-0.0360%-0.016-54%0.012-399%0.012-399%
 EOD+3 -5MRQTTM+0 -0YOY+3 -265Y+13 -1710Y+13 -17

3.2. Fundamental Score

Let's check the fundamental score of BiVictriX Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.801
Price to Book Ratio (EOD)Between0-12.398
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than19.852
Current Ratio (MRQ)Greater than110.141
Debt to Asset Ratio (MRQ)Less than10.128
Debt to Equity Ratio (MRQ)Less than10.146
Return on Equity (MRQ)Greater than0.15-0.631
Return on Assets (MRQ)Greater than0.05-0.550
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of BiVictriX Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.874
Ma 20Greater thanMa 5011.413
Ma 50Greater thanMa 10011.525
Ma 100Greater thanMa 20011.298
OpenGreater thanClose11.500
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in GBP. All numbers in thousands.

Summary
Total Assets4,536
Total Liabilities579
Total Stockholder Equity3,957
 As reported
Total Liabilities 579
Total Stockholder Equity+ 3,957
Total Assets = 4,536

Assets

Total Assets4,536
Total Current Assets3,965
Long-term Assets571
Total Current Assets
Cash And Cash Equivalents 3,287
Net Receivables 565
Other Current Assets 113
Total Current Assets  (as reported)3,965
Total Current Assets  (calculated)3,965
+/-0
Long-term Assets
Property Plant Equipment 571
Long-term Assets  (as reported)571
Long-term Assets  (calculated)571
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities391
Long-term Liabilities188
Total Stockholder Equity3,957
Total Current Liabilities
Short-term Debt 107
Accounts payable 112
Other Current Liabilities 172
Total Current Liabilities  (as reported)391
Total Current Liabilities  (calculated)391
+/-0
Long-term Liabilities
Other Liabilities 188
Long-term Liabilities  (as reported)188
Long-term Liabilities  (calculated)188
+/-0
Total Stockholder Equity
Common Stock661
Retained Earnings -6,346
Accumulated Other Comprehensive Income 424
Other Stockholders Equity 9,218
Total Stockholder Equity (as reported)3,957
Total Stockholder Equity (calculated)3,957
+/-0
Other
Capital Stock661
Cash and Short Term Investments 3,287
Common Stock Shares Outstanding 66,115
Liabilities and Stockholders Equity 4,536
Net Debt -2,992
Net Invested Capital 3,957
Net Tangible Assets 3,957
Net Working Capital 3,574
Property Plant and Equipment Gross 768
Short Long Term Debt Total 295



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
348
266
7,736
6,881
4,536
4,5366,8817,736266348
   > Total Current Assets 
347
265
7,673
6,542
3,965
3,9656,5427,673265347
       Cash And Cash Equivalents 
211
129
7,530
6,063
3,287
3,2876,0637,530129211
       Net Receivables 
133
133
136
260
565
565260136133133
   > Long-term Assets 
1
1
63
339
571
5713396311
       Property Plant Equipment 
1
1
63
339
571
5713396311
> Total Liabilities 
38
86
330
554
579
5795543308638
   > Total Current Liabilities 
38
86
330
379
391
3913793308638
       Short-term Debt 
0
0
0
71
107
10771000
       Accounts payable 
20
25
263
69
112
112692632520
       Other Current Liabilities 
11
61
67
239
172
172239676111
   > Long-term Liabilities 
0
25
671
175
188
188175671250
       Other Liabilities 
0
0
0
0
188
1880000
> Total Stockholder Equity
310
180
7,406
6,327
3,957
3,9576,3277,406180310
   Common Stock
1
1
1
661
661
661661111
   Retained Earnings -6,346-3,849-1,519-1,094-685
   Capital Surplus 
0
0
1,428
0
0
001,42800
   Treasury Stock00000
   Other Stockholders Equity 
994
1,273
1,429
9,218
9,218
9,2189,2181,4291,273994



Balance Sheet

Currency in GBP. All numbers in thousands.




Cash Flow

Currency in GBP. All numbers in thousands.




Income Statement

Currency in GBP. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-151
Gross Profit-151-151
 
Operating Income (+$)
Gross Profit-151
Operating Expense-2,975
Operating Income-2,975-3,126
 
Operating Expense (+$)
Research Development2,110
Selling General Administrative738
Selling And Marketing Expenses0
Operating Expense2,9752,848
 
Net Interest Income (+$)
Interest Income4
Interest Expense--4
Other Finance Cost-4
Net Interest Income4
 
Pretax Income (+$)
Operating Income-2,975
Net Interest Income4
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,971-2,979
EBIT - interestExpense = -2,971
-2,971
-2,501
Interest Expense-4
Earnings Before Interest and Taxes (EBIT)-2,975-2,975
Earnings Before Interest and Taxes (EBITDA)-2,824
 
After tax Income (+$)
Income Before Tax-2,971
Tax Provision--474
Net Income From Continuing Ops-2,497-2,497
Net Income-2,497
Net Income Applicable To Common Shares-2,497
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,975
Total Other Income/Expenses Net4-4
 

Technical Analysis of Bivictrix
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Bivictrix. The general trend of Bivictrix is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Bivictrix's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BiVictriX Therapeutics PLC.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 11.50 < 11.50 < 11.50.

The bearish price targets are: 11.05 > 11.01 > 11.00.

Tweet this
BiVictriX Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BiVictriX Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BiVictriX Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BiVictriX Therapeutics PLC. The current macd is -0.04719093.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Bivictrix price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Bivictrix. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Bivictrix price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
BiVictriX Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartBiVictriX Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BiVictriX Therapeutics PLC. The current adx is 46.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Bivictrix shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
BiVictriX Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BiVictriX Therapeutics PLC. The current sar is 11.67.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BiVictriX Therapeutics PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BiVictriX Therapeutics PLC. The current rsi is 57.87. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
BiVictriX Therapeutics PLC Daily Relative Strength Index (RSI) ChartBiVictriX Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BiVictriX Therapeutics PLC. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Bivictrix price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
BiVictriX Therapeutics PLC Daily Stochastic Oscillator ChartBiVictriX Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BiVictriX Therapeutics PLC. The current cci is -0.78740157.

BiVictriX Therapeutics PLC Daily Commodity Channel Index (CCI) ChartBiVictriX Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BiVictriX Therapeutics PLC. The current cmo is 35.98.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
BiVictriX Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartBiVictriX Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BiVictriX Therapeutics PLC. The current willr is -28.57142857.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Bivictrix is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
BiVictriX Therapeutics PLC Daily Williams %R ChartBiVictriX Therapeutics PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BiVictriX Therapeutics PLC.

BiVictriX Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BiVictriX Therapeutics PLC. The current atr is 0.35461883.

BiVictriX Therapeutics PLC Daily Average True Range (ATR) ChartBiVictriX Therapeutics PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BiVictriX Therapeutics PLC. The current obv is 714,859.

BiVictriX Therapeutics PLC Daily On-Balance Volume (OBV) ChartBiVictriX Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BiVictriX Therapeutics PLC. The current mfi is 10.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BiVictriX Therapeutics PLC Daily Money Flow Index (MFI) ChartBiVictriX Therapeutics PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BiVictriX Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-25MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

BiVictriX Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BiVictriX Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.874
Ma 20Greater thanMa 5011.413
Ma 50Greater thanMa 10011.525
Ma 100Greater thanMa 20011.298
OpenGreater thanClose11.500
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Bivictrix with someone you think should read this too:
  • Are you bullish or bearish on Bivictrix? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Bivictrix? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BiVictriX Therapeutics PLC

I send you an email if I find something interesting about BiVictriX Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about BiVictriX Therapeutics PLC.

Receive notifications about BiVictriX Therapeutics PLC in your mailbox!